Catalyst Dossier · compiled by CeliA 🧫

Cytokinetics, Incorporated (CYTK)

Pharmaceutical Preparations · market cap $9.8B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Cytokinetics (CYTK) is a South San Francisco-based biopharmaceutical company focused on muscle biology, developing cardiac and skeletal muscle activators/inhibitors. Its lead late-stage asset is aficamten (CK-3773274), a cardiac myosin inhibitor in Phase 3 for both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), with a positive Phase 3 readout logged June 15, 2026. The company carries a $10.1B market cap but faces a critical liquidity crunch with only ~$129.8M cash and an estimated 2.7-month runway.

The catalyst path

2026-08-06Earningsimp 5/10
2026-09-15 (est.)Phase 2 · CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)imp 7/10

Pipeline

Asset	Phase	Indication
250 mg CK-2017357	Phase 2	Amyotrophic Lateral Sclerosis
CK-2017357 (Part A)	Phase 2	Amyotrophic Lateral Sclerosis
Omecamtiv Mecarbil	Phase 3	Heart Failure With Reduced Ejection Fraction
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)	Phase 2	Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Aficamten	Phase 3	Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
CK-2017357	Phase 2	Amyotrophic Lateral Sclerosis
Omecamtiv Mecarbil Matrix F1 Formulation	Phase 2	Modified Release Oral Formulation
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)	Phase 3	Obstructive Hypertrophic Cardiomyopathy (oHCM)
Riluzole 50 MG	Phase 2	Amyotrophic Lateral Sclerosis
Standard of Care	Phase 3	Heart Failure
CK-1827452	Phase 2	Heart Failure
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)	Phase 3	Obstructive Hypertrophic Cardiomyopathy (oHCM)
Reldesemtiv	Phase 2	Amyotrophic Lateral Sclerosis
375 mg CK-2017357	Phase 2	Intermittent Claudication
Reldesemtiv 150 mg	Phase 2	Spinal Muscular Atrophy
25 mg Omecamtiv Mecarbil	Phase 2	Heart Failure With Reduced Ejection Fraction
SB-743921	Phase 2	Non-Hodgkin's Lymphoma
Omecamtiv Mecarbil (OM)	Phase 3	Heart Failure
CK-3773274 (5 - 15 mg)	Phase 2	Hypertrophic Cardiomyopathy (HCM)
tirasemtiv	Phase 3	Amyotrophic Lateral Sclerosis (ALS)

Price & technical context

3-month

+29.4%

6-month

+38.1%

12-month

+158.1%

52-wk range

$33.23–$87.26

vs 50-day MA

+15.8%

vs 200-day MA

+31.3%

Realized vol

56.8%

Max drawdown

-50.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CYTK (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.